Defense Advanced Research Projects AgencyTagged Content List

Prevention and Therapy

Biomedical technologies designed to thwart initial infection or injury, or enable faster healing afterward

Showing 23 results for Therapy + Programs RSS
Warfighters are travelers, and the bodily inconveniences suffered by travelers, such as jet lag and traveler's diarrhea, can seriously degrade operational readiness and even determine mission success or failure. To maximize warfighter performance, the ADvanced Acclimation and Protection Tool for Environmental Readiness (ADAPTER) program will develop systems that provide warfighters greater control over their own physiology.
The Autonomous Diagnostics to Enable Prevention and Therapeutics (ADEPT) program supports individual troop readiness and total force health protection by developing technologies to rapidly identify and respond to threats posed by natural and engineered diseases and toxins. A subset of ADEPT technologies specifically support use by personnel with minimal medical training, delivering centralized laboratory capabilities even in the low-resource environments typical of many military operations. The program is part of a portfolio of DARPA-funded research aimed at providing options for preempting or mitigating constantly evolving infectious disease threats.
The Battlefield Medicine program supports military readiness in far-forward deployed settings by overcoming logistical obstacles to manufacturing and delivery of urgently needed pharmaceutical products used to treat emerging threats.
The Biostasis program aims to extend the time for lifesaving medical treatment, often referred to as “the Golden Hour,” following traumatic injury or acute infection, thus increasing survivability for military personnel operating in far-forward conditions with limited access to medical professionals or trauma centers. To do so, Biostasis is developing novel chemical biology approaches that reversibly and controllably slow biological systems without cold-chain to stabilize and protect their functional capacity until medical intervention is possible.
The Dialysis-Like Therapeutics (DLT) program aims to support force protection and military readiness by improving critical care in low-resource environments and delivering a new tool for rapid response to emerging infectious disease threats. DLT specifically addresses a life-threatening blood infection known as sepsis, but DARPA is working to expand the DLT technology to also mitigate threats from harmful bacteria, viruses, fungi, and toxic agents in the blood.